Targeting DNA repair pathways in prostate cancer

Who could benefit from this research

What this research studies

This research investigates how targeting the DNA damage repair (DDR) pathway can improve treatment outcomes for patients with non-castrate prostate cancer. The approach involves using a combination of therapies, including a PARP inhibitor, androgen deprivation therapy, and surgery, to enhance the effectiveness of treatment. The study aims to determine if these targeted therapies can lead to better responses and potentially cure prostate cancer in patients with specific genetic alterations. Patients will be enrolled in a flexible, randomized clinical trial to assess the effectiveness of this multimodal treatment strategy.

Why it matters

Where this research is happening

• Sloan-Kettering Inst Can Research
  New York, United States Active

Researchers

• Principal investigator: Scher, Howard I — Sloan-Kettering Inst Can Research
• Study coordinator: Scher, Howard I

Related research

Other NIH-funded projects on the same topics.

• Ariginine-depleting therapy plus chemotherapy for aggressive variant prostate cancers

  This project tests whether removing arginine from the body enhances chemotherapy for men with a difficult-to-treat prostate cancer subtype.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11391400

• Targeting master regulators to overcome AR-driven resistance in advanced prostate cancer

  This grant explores how cancer cells rewire their growth signals to resist AR-targeted therapies in advanced prostate cancer and tests new ways to block those master regulators.

  NIH research State University of New York at Buffalo · Amherst, United States · NIH-11369845

• Lowering arginine with chemotherapy for aggressive prostate cancer

  Looks at whether lowering a nutrient called arginine together with platinum‑taxane chemotherapy can help men with aggressive, treatment‑resistant prostate cancer.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11174404

• Targeting key regulators in advanced prostate cancer that resist standard treatments

  This research looks for new ways to treat advanced prostate cancer that has stopped responding to common hormone therapies.

  NIH research State University of New York at Buffalo · Amherst, United States · NIH-11159586

• Investigating the impact of arginine depletion with chemotherapy in aggressive prostate cancers

  This study is looking at how lowering levels of an amino acid called arginine might make chemotherapy work better for men with aggressive prostate cancer that doesn't respond well to regular treatments.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-10932183

• Targeting key factors in advanced prostate cancer treatment resistance

  This study is looking at how certain proteins in prostate cancer cells help the cancer resist treatments that target hormones, with the goal of finding new ways to improve treatment for patients who aren't responding to current therapies.

  NIH research State University of New York at Buffalo · Amherst, United States · NIH-10904810

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.